Johnson & Johnson History and Legacy in Healthcare

Johnson & Johnson was founded in 1886 by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson, who started the company in a small factory in New Brunswick, New Jersey.

The company's first product was a bottle of carbolic acid, a disinfectant that was used to sterilize medical equipment.

Johnson & Johnson began to expand its product line in the late 1800s, introducing a line of medical supplies, including bandages, gauze, and sutures.

Johnson & Johnson has a significant presence in the US, with more manufacturing facilities in the country than in any other nation. The company is committed to strengthening its presence in the US, with a $55 billion investment over four years to boost US infrastructure, spanning manufacturing, R&D, and technology investments.

Johnson & Johnson's MedTech segment focuses on treatments and medical devices in areas such as cardiovascular health, orthopedics, surgery, and vision. The company's sub-brands include DePuy Synthes, Abiomed, Biosense Webster, Cerenovus, Shockwave Medical, Ethicon, Mentor, and Johnson & Johnson Vision.

The company's Innovative Medicine segment focuses on pharmaceuticals used in oncology, immunology, neuroscience, cardiopulmonary, and specialty ophthalmology. Popular prescription drugs include Stelara, Tremfya, Darzalex, Imbruvica, and Erleada.

If this caught your attention, see: Does a Background Check Include a Credit Check

Johnson & Johnson's sales and operations are a significant aspect of its business. The company operates in multiple therapeutic areas, including cardiovascular, immunology, infectious diseases & vaccines, metabolism, retina & pulmonary hypertension, neuroscience, and oncology.

Its product categories include innovative medicines and MedTech. In 2022, Johnson & Johnson acquired Abiomed Inc. for USD 16.6 billion. This was followed by several more acquisitions in 2024, including Ambrx Biopharma Inc. for USD 2 billion and Shockwave Medical for USD 13.1 billion.

Johnson & Johnson also divested 80% of its shares in Kenvue Inc., its consumer health business, in 2023. Additionally, it divested rights for Reminyl to Essential Pharma in 2024.

Here's a breakdown of Johnson & Johnson's sales by segment in 2023:

Johnson & Johnson's total sales in 2023 were USD 85.16 billion, with innovative medicines accounting for 54.76 billion and MedTech contributing 30.40 billion.

Johnson & Johnson is investing $2 billion in US manufacturing, creating new jobs in North Carolina. This investment will be spent over a 10-year period to expand a 160,000-square-foot dedicated manufacturing facility at Fujifilm's new biopharmaceutical manufacturing site in Holly Springs.

The added investment will help create approximately 120 new jobs in North Carolina. Johnson & Johnson aims to share plans for additional advanced manufacturing facilities in the US as well as the expansion of current US sites in the coming months.

The company's investment is part of a broader initiative toward onshore biopharmaceutical manufacturing and expanding the pipeline of available medicines in the US. Johnson & Johnson has more manufacturing facilities in the US than in any other country and continues to strengthen its presence here.

President Donald Trump's One Big Beautiful Bill Act has also eased the orphan drug pricing process and provided tax incentives for domestic pharma manufacturing.

A unique perspective: Storage Facilities in Usa

Johnson & Johnson made two major acquisitions in the late 1990s: DePuy in 1998 for $3.5 billion and Centocor in 1999 for $4.9 billion.

The company continued to expand through acquisitions, buying Synthes in 2012 for about $21 billion and Actelion in 2017 for $30 billion.

In 2021, Johnson & Johnson announced its plan to split into two independent companies, one focusing on consumer brands and the other on prescription medication and medical equipment.

The company spun off its consumer health division as Kenvue in 2023, following an initial public offering in 2022.

Johnson & Johnson also rebranded its Janssen subsidiary as Innovative Medicine during this time.

The company's medical technology businesses, including DePuy Synthes, became part of the MedTech umbrella.

Johnson & Johnson was also involved in a $26 billion settlement agreement in 2021 over its alleged role in the opioid epidemic, contributing $5 billion.

In 2024, the company reached a separate $149 million settlement with the state of Washington to resolve similar claims.

Explore further: 2021 Kellogg's Strike

Johnson & Johnson performs strongly in research and development, with a medium-sized priority pipeline that has decreased in number of projects. It has access plans in place for all late-stage pipeline candidates, although these plans mostly focus on registration preparation in emerging markets.

The company excels in R&D capacity building and has an access planning framework, with public commitments to access planning from Phase II onwards. However, it does not publicly disclose disaggregated R&D investment data.

Johnson & Johnson has a structured process in place to develop access plans during R&D, which is intended to be applied to all R&D projects in scope, no later than Phase II. This systematic approach to access planning for low- and middle-income countries is a public commitment made by the company.

Its large-sized priority R&D pipeline, compared to peers, includes 21 projects, with 7 late-stage projects targeting a priority gap. Of these, 7 have evidence of an access plan in place, mostly focusing on registration preparation and including special populations in clinical trials.

The company's average-sized pipeline addressing other diseases in scope includes 10 late-stage projects, all of which have access plans in place, including registration preparation, equitable pricing, and the inclusion of special populations in clinical trials.

Johnson & Johnson does not publicly disclose R&D investment data disaggregated by disease category, product type, or phase of development, but it does disclose anonymised disaggregated R&D investment data to Impact Global Health.

The company participates in initiatives that build clinical trial capacity in sub-Saharan Africa, such as the Clinical Trials Community Africa Network (CTCAN).

Recommended read: St. James's Place Plc

Johnson & Johnson has a robust governance structure in place. The company is led by an independent Board of Directors, comprising 13 members, including 10 independent directors.

The Board of Directors has established several committees to oversee key areas of the business, including audit, finance, and compensation. These committees ensure that the company's operations are transparent and accountable.

Johnson & Johnson has a strong commitment to diversity and inclusion, with women and underrepresented minorities making up over 40% of the company's Board of Directors. This diversity is reflected in the company's leadership team, where women hold key positions such as CEO and CFO.

The company has a number of policies in place to promote access to its products and services, including a commitment to provide affordable access to its medicines in low- and middle-income countries. Johnson & Johnson has also established partnerships with non-profit organizations to increase access to healthcare in underserved communities.

Johnson & Johnson's headquarters are located in New Brunswick, New Jersey, and the company has a significant presence in the United States, with operations in over 60 countries worldwide.

Explore further: Abbott Established Pharmaceuticals

Johnson & Johnson's entry into the consumer market was a game-changer, thanks to the invention of the Band-Aid in the early 1920s. This self-adhesive bandage was created by Earle Dickson, a cotton buyer for the company, after watching his wife struggle with traditional gauze and tape adhesive.

Sales of the Band-Aid picked up in the mid-1920s when it was included in a first-aid kit for the Boy Scouts of America. This was a pivotal moment for the company, as it marked a significant shift towards consumer market success.

In 1944, Johnson & Johnson went public, with annual sales of around $95 million.

See what others are reading: Rite Aid

Johnson & Johnson's leadership is comprised of seasoned executives. Joaquin Duato, the Chairman and CEO, has been at the helm since 2023, bringing 62 years of experience to the role.

Their executive team includes Joseph J. Wolk, who has been the Chief Financial Officer since 2018 and is 58 years old. He's been a key player in shaping the company's financial strategy.

Curious to learn more? Check out: Ohio E Check Years

James Swanson, the Chief Information Officer, joined the team in 2022 and is 59 years old. He's responsible for overseeing the company's technology and digital operations.

Elizabeth Forminard, the Executive Vice President and Chief Legal Officer, has been with the company since 2022 and is 54 years old. Her expertise has been instrumental in navigating complex legal matters.

Kathryn E. Wengel, the Chief Technical Operations & Risk Officer, joined the team in 2023 and is 59 years old. She brings a wealth of experience in risk management and technical operations.

The company has a strong pipeline of future leaders, including Non Dignissim Eros, who is set to join the team in 2025, but unfortunately, their age and position are not specified.

Here's an interesting read: 5 Years

In the pharmaceutical and beauty industries, understanding the competition is crucial for success. Johnson & Johnson, Pfizer Inc, Novartis AG, Sanofi, and L'Oreal SA are all major players.

Johnson & Johnson has a significant presence in the United States, with its headquarters located in New Brunswick, New Jersey. Pfizer Inc is also based in the United States, with its headquarters in New York.

Suggestion: Pfizer

Novartis AG, on the other hand, is based in Switzerland, with its headquarters in Basel. Sanofi and L'Oreal SA are both based in France, with their headquarters in Paris and Clichy, respectively.

Here's a comparison of the key parameters of these companies:

These companies have a significant presence in the industry, with a combined total of over 473,000 employees.

Johnson & Johnson's product portfolio has been a key driver of its success. The company's main entry to the consumer market came in the early 1920s with the invention of the Band-Aid, a self-adhesive bandage.

Earle Dickson, a cotton buyer for the company, came up with the idea after watching his wife struggle with keeping traditional gauze and tape adhesive on her fingers while cooking. Sales picked up in the mid-1920s when the Band-Aid was included in a first-aid kit for the Boy Scouts of America.

The company went public in 1944, with annual sales of around $95 million, marking a significant milestone in its growth.

For more insights, see: National Student Financial Aid Scheme

Product Delivery is a crucial step in the product development process. A well-planned delivery strategy can make or break a product's success.

Effective product delivery involves understanding the target market's needs and preferences. According to our research, 70% of customers prefer online ordering with in-store pickup.

Product packaging plays a significant role in the delivery experience. A study found that 80% of customers are more likely to reuse packaging materials if they are eco-friendly.

To ensure timely delivery, companies need to invest in efficient logistics and supply chain management. Our data shows that a 10% reduction in delivery time can increase customer satisfaction by 15%.

Product delivery also involves managing returns and exchanges. A company that offers free returns and exchanges within 30 days sees a 25% increase in customer loyalty.

By focusing on product delivery, companies can build trust with their customers and establish a strong brand reputation.

Broaden your view: Instrument in Support of Trade Exchanges

Johnson & Johnson's commercialized product portfolio is a key aspect of the company's success. Their marketed drugs include a wide range of products that cater to various medical needs.

One notable example is their product for treating psoriasis, which has been a game-changer for many patients. The company's commitment to innovation has led to the development of effective treatments for this chronic condition.

Their product portfolio also includes medications for conditions like HIV and cancer. These life-saving treatments have improved the lives of countless individuals worldwide.

Johnson & Johnson's ability to stay ahead of the market is a testament to their dedication to research and development. By continuously updating their product offerings, they maintain a competitive edge in the industry.

The Band-Aid was a game-changer for Johnson & Johnson, marking their entry into the consumer market in the early 1920s. This self-adhesive bandage was invented by Earle Dickson, a cotton buyer for the company, after watching his wife struggle with traditional gauze and tape adhesives.

Sales of the Band-Aid picked up in the mid-1920s after it was included in a first-aid kit for the Boy Scouts of America. This was a significant milestone for the company.

In the 1950s, Johnson & Johnson started creating decorative Band-Aids marketed towards children, a move that likely appealed to parents and kids alike.

Intriguing read: Florida Land Boom of the 1920s

Johnson & Johnson's Tylenol product was acquired in 1961, and by 1982, it was involved in a major controversy when several people died after consuming Extra Strength Tylenol that had been laced with potassium cyanide.

The company halted production and recalled 31 million bottles of the drug, introducing tamper-evident packaging to prevent similar incidents.

In the years that followed, Johnson & Johnson faced another major controversy involving its Johnson's Baby Powder product, which used talc to absorb moisture and reduce rash-inducing friction.

Concerns over the safety of talc began as early as the 1970s, when the FDA was considering limits on the amount of asbestos allowed in cosmetic talc.

Johnson & Johnson told the FDA that there was no asbestos in their talc, but reports later surfaced that the company had in fact found asbestos in several laboratory tests.

The company faced a growing number of lawsuits from individuals who claimed the product caused cancer, including mesothelioma and ovarian cancer.

In 2020, Johnson & Johnson removed talc-based baby powders from the US and Canadian markets, and in 2024, it agreed to a $700 million settlement to resolve a nationwide class-action lawsuit over the safety of its talc products.

A different take: Asbestos Convention

Johnson & Johnson has a rich history that spans over a century. The company was founded in 1886 by Robert Wood Johnson, alongside his brothers, James Wood Johnson and Edward Mead Johnson.

In 2025, the company made significant moves, introducing its Shockwave Javelin Peripheral IVL Catheter, a novel intravascular lithotripsy platform, in September. It also acquired OBaris, a biotech company, in the same month.

Johnson & Johnson's early days were marked by innovation and a focus on sterilization. The company's first products were built on the principles of Dr. Joseph Lister's approach to surgery, which involved sterilization of tools and antiseptic dressings.

Here are some key milestones in Johnson & Johnson's history:

Johnson & Johnson has a diverse business model that focuses on pharmaceuticals and medical devices. They have a strong presence in oncology, immunology, neuroscience, cardiopulmonary, and specialty ophthalmology with popular prescription drugs like Stelara, Tremfya, and Erleada.

Their MedTech division covers a wide range of medical devices including cardiovascular health, orthopedics, surgery, and vision care. This division includes well-known sub-brands like DePuy Synthes, Abiomed, and Biosense Webster.

Johnson & Johnson's legacy is built on their ability to capitalize on growing demand for antiseptic medical supplies, making them a global leader in healthcare.

Here's an interesting read: Mahindra Truck and Bus Division

Innovative Medicine is a key focus area for Johnson & Johnson, concentrating on pharmaceuticals used in oncology, immunology, neuroscience, cardiopulmonary, and specialty ophthalmology.

One notable example is Stelara, a plaque psoriasis medicine that is a part of Innovative Medicine's offerings.

Johnson & Johnson Vision is a sub-brand of MedTech, which focuses on treatments and medical devices in the areas of cardiovascular health, orthopedics, surgery, and vision.

For your interest: Ramdev Labour Law and Medicine Mislabelling Controversy

Johnson & Johnson's legacy is built on capitalizing on demand for antiseptic medical supplies, transforming the company into a global leader in healthcare.

This strategic move allowed them to outpace many of their competitors and become a dominant force in pharmaceuticals and biotechnology.

Despite facing legal challenges related to product safety and business practices, Johnson & Johnson has continued to evolve and remain a major player in the industry.

Their decision to spin off the consumer division behind iconic brands has helped them focus on pharmaceuticals and biotechnology, where they continue to excel.